AI assistant
UCB — Major Shareholding Notification 2021
Aug 9, 2021
4017_mrq_2021-08-09_192582d3-bdcc-4482-83a7-4d8e1f6157eb.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Transparency notification FMR LLC.
- Notification referring to situation on 30 July 2021
- Threshold crossed: 5%
- Latest holding: 3.63 %
Brussels (Belgium), 9 August 2021 – 20:00 (CEST) – regulated information
1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, U.S.A.), on 5 August 2021.
FMR LLC., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its holding in UCB shares with voting rights has increased and has crossed for the first time the 5% threshold on 30 July 2021.
On 30 July 2021, FMR LLC. (taking into account the holding of its affiliates) owned 9 728 407 UCB shares with voting rights, representing 5.00% of the total number of shares issued by the company (194 505 658).
2. Content of the notification
- Reason for the notification: Acquisition or disposal of voting securities or voting rights.
- Notification by: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:
| Name | Address (for legal entities) | |
|---|---|---|
| FMR LLC | 245 Summer Street, Boston, Massachusetts, 02210 |
- Date on which the threshold is crossed: 30 July 2021.
- Threshold crossed (in %): 5%.
- Denominator: 194 505 658.
• Notified details:
| A) Voting rights | Previous notification | After the transaction | |||
|---|---|---|---|---|---|
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities |
Linked to securities | Not linked to the securities |
|
| FMR LLC | 0 | 0 | 0,00% | ||
| FIAM LLC | 344.879 | 907.044 | 0,47% | ||
| Fidelity Institutional Asset Management Trust Company |
161.950 | 326.340 | 0,17% | ||
| Fidelity Management & Research Company LLC |
6.086.793 | 7.719.146 | 3,97% | ||
| FMR Investment Management (UK) Limited |
467.322 | 657.499 | 0,34% | ||
| Strategic Advisers LLC | 0 | 118.378 | 0,06% | ||
| Subtotal | 7.060.944 | 9.728.407 | 5,00% | ||
| TOTAL | 9.728.407 | 0 | 5,00% | 0,00% |
| B) Equivalent financial instruments | After the transaction | |||||
|---|---|---|---|---|---|---|
| Holders of equivalent financial instruments |
Type of financial instrument | Expiration date Exercise period or date |
# of voting rights that may be acquired if the instrument is exercised |
% of voting rights | Settlement | |
| TOTAL | 0 | 0,00% |
| TOTAL (A & B) | # of voting rights % of voting rights | ||
|---|---|---|---|
| CALCULATE | 9.728.407 | 5,00% |
• Chain of controlled undertakings through which the holding is effectively held:
Fidelity Institutional Asset Management Trust Company and FIAM LLC are controlled by FIAM Holdings LLC, FIAM Holdings LLC is controlled by FMR LLC Fidelity Management & Research Company LLC is controlled by FMR LLC FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC Strategic Advisers LLC is controlled by Fidelity Advisory Holdings LLC Fidelity Advisory Holdings LLC is controlled by FMR LLC FMR LLC is not a controlled entity.
3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.
Investor Relations
Antje Witte Investor Relations, UCB
T +32 2 559 94 14, [email protected]
Corporate Communications
Laurent Schots Media Relations, UCB
T+32.2.559.92.64 [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news